Geographic Atrophy in Modern Clinical Practice: Examining Di -

Thank you for attending.

Please click "Next Page" to proceed to the post-test, evaluation, and proceed to the claim credit page.

Note for ODs: COPE guidelines dictate that in order to receive credit, learners must remain present at the synchronous virtual activity until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.

Scroll back to top

Details

Overview
As treatments for geographic atrophy (GA) are entering the market, a key practice for primary eye care providers will be identification of GA lesions prior to referral to a retina specialist for administration of therapy.
David R. Lally, MD, will provide a thorough review on GA and discuss the most important data for the newly approved and pipeline drug candidates.
Note About Obtaining Credit:
You must remain at the synchronous virtual activity until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.

This activity is supported by unrestricted educational grants from Iveric Bio and Carl Zeiss Meditec.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Summarize the prevalence of age-related macular degeneration (AMD) and geographic atrophy (GA) and define the burden of illness linked specifically to GA
- Comprehend and explain the pathogenesis of GA
- Describe GA disease detection and factors influencing progression
- Appraise the therapies targeting GA that have previously been explored
- Articulate the most important data related to drug candidates in the pipeline, with a special emphasis on those candidates furthest along in development
Accreditation
Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator.
This activity, COPE Activity Number 126089, is accredited by COPE for continuing education for optometrists. This course is approved for 1.5 hours of CE.
Course #: 84468-TD
Activity #: 126089
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Participation Method
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Faculty and Disclosures
David R. Lally, MD
Retina Research Institute at New England Retina Consultants
Assistant Professor
University of Massachusetts
Springfield, MA

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
David R. Lally, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Allergan, Annexon, Apellis Pharmaceuticals, EyePoint Pharmaceuticals, Genentech, Novartis, Ocuphire Pharma, Théa Pharma, and Roche. Grant/Research Support: Annexon, Apellis Pharmaceuticals, Chengdu Kanghong Biotechnology, Emmes Corporation, EyePoint Pharmaceuticals, Neurotech, Notal Vision, Novartis, Kodiak Biosciences, Ocuphire Pharma, Opthea, Oxurion, and Stealth Biotherapeutics. Speaker's Bureau: Alimera Sciences, Allergan, Annexon, Apellis Pharmaceuticals, Genentech, and Novartis. Shareholder: Ocuphire Pharma.
The Evolve staff, planners, and reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Iveric Bio, or Carl Zeiss Meditec.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Note About Obtaining Credit:
You must remain logged into the synchronous virtual activity until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 06/01/2023

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Title

Share on ReachMD